Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas — (June 24, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company’s […]
Research Journal Features Genprex Collaborators’ Abstract Detailing Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer AUSTIN, Texas — (April 22 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its […]
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma AUSTIN, Texas — (Sept. 9, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected […]
Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Presentation to Highlight the Promise of Novel Gene Therapies to Transform Cancer and Diabetes Treatments
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes
Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.